Relay Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:RLAY) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -102.49 M-74.41 M-229.49 M-300.32 M-249.11 M-235.46 M -213.36 M Cash from investing activities 81.67 M-479.51 M-188.75 M257.63 M-41.08 M192.8 M 183.24 M Cash from financing activities 426.51 M388.09 M289.91 M34.75 M270.15 M1.6 M — Free cash flow -102.49 M-74.41 M-229.49 M-300.32 M-249.11 M-235.46 M -213.36 M

News

Two Months. $10 Million. A Sputnik Moment for AI.

Relay Therapeutics: Zovegalisib Is Becoming A Platform In Disguise (NASDAQ:RLAY)

Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies Transcript

Rising Bond Yields Weigh on Stocks

Stocks Pressured by Tech Weakness and Rising Bond Yields

This Biotech's Drug Just Wiped The Floor With Forecasts

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates

Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates

Recursion Pharmaceuticals May Be Losing Ground To Its Peers (NASDAQ:RXRX)

Relay Therapeutics, Inc. (RLAY) Discusses Zovegalisib Triplet Data and First-Line Breast Cancer Strategy Transcript

Oppenheimer reiterates Relay Therapeutics stock rating on trial data

Relay reports phase 1/2 data for breast cancer drug zovegalisib